Ken Griffin Biodesix Inc Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$1.21 - $1.71 $605 - $855
500 New
500 $0
Q4 2023

Feb 14, 2024
SELL
$1.2 - $2.13 $1,800 - $3,195
-1,500 Reduced 65.22%
800 $1,000
Q3 2023

Nov 14, 2023
BUY
$1.04 - $1.74 $2,392 - $4,002
2,300 New
2,300 $3,000
Q4 2022

Feb 14, 2023
SELL
$0.98 - $2.3 $33,320 - $78,200
-34,000 Reduced 97.42%
900 $2,000
Q3 2022

Nov 14, 2022
SELL
$1.24 - $2.89 $41,788 - $97,393
-33,700 Reduced 49.13%
34,900 $44,000

Others Institutions Holding BDSX

# of Institutions
52
Shares Held
53.1M
Call Options Held
500
Put Options Held
11.5K
View Full List

About BIODESIX INC

BDSX Quotes by TradingView
  • Ticker BDSX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 39,982,000
  • Market Cap $55.2M
  • Description
  • Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...
More about BDSX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email